28521299|t|Isradipine attenuates MPTP - induced dopamine neuron degeneration by inhibiting up-regulation of L-type calcium channels and iron accumulation in the substantia nigra of mice
28521299|a|The aim of this study is to investigate the effects of L-type calcium channels (LTCCs) on MPTP - induced dopamine (DA) neuron degeneration and iron accumulation in the substantia nigra (SN) of mice. By real-time PCR and western blots, we first quatified expressions of L-type Cav1.2 and Cav1.3 calcium channel α1 subunits in the SN of experimental mice treated with MPTP. We found that the expressions of Cav1.2 and Cav1.3 calcium channel α1 subunits markedly increased after MPTP treatment for 2 and 3 weeks. Secondly, we observed the effects of isradipine, a LTCC antagonist, on MPTP - induced DA neuron degeneration and iron accumulation in the SN. Our results showed that isradipine treatment prevented against MPTP - induced Cav1.2 and Cav1.3 calcium channel α1 subunits up-regulation in the SN. We also found that isradipine prevented against MPTP - induced DA neuron depletion in the SN and partly restored the DA content in the striatum. Moreover, we found that isradipine inhibited the increase of iron positive cells in the SN of the MPTP - treated mice. Finally, we investigated the effects of isradipine on cellular iron accumulation in the dopaminergic MES23.5 cell line. Our studies showed that MPP+ treatment accelerated iron influx in the MES23.5 cells. Treatment with Bayk8644 further aggravated iron accumulation. Treatment with isradipine prevented against MPP+ - induced iron influx in the MES23.5 cells. These results suggest that up-regulation of LTCCs may be responsible for the DA neuron degeneration in the MPTP - treated mice, The LTCCs may directly contribute to iron influx into DA neurons, and isradipine may suppress cellular iron accumulation and prevents neurodegeneration.
28521299	0	10	Isradipine	T109,T121	C0071304
28521299	11	21	attenuates	T052	C0599946
28521299	22	26	MPTP	T109,T131	C0000097
28521299	29	36	induced	T046	C0007994
28521299	37	52	dopamine neuron	T025	C1512035
28521299	53	65	degeneration	T049	C0027746
28521299	69	79	inhibiting	T052	C3463820
28521299	80	93	up-regulation	T044	C0041904
28521299	97	120	L-type calcium channels	T116,T123	C0288263
28521299	125	166	iron accumulation in the substantia nigra	T033	C4022785
28521299	170	174	mice	T015	C0025929
28521299	191	196	study	T062	C0008972
28521299	203	214	investigate	T169	C1292732
28521299	219	229	effects of	T080	C1704420
28521299	230	253	L-type calcium channels	T116,T123	C0288263
28521299	255	260	LTCCs	T116,T123	C0288263
28521299	265	269	MPTP	T109,T131	C0000097
28521299	272	279	induced	T046	C0007994
28521299	280	300	dopamine (DA) neuron	T025	C1512035
28521299	301	313	degeneration	T049	C0027746
28521299	318	359	iron accumulation in the substantia nigra	T033	C4022785
28521299	361	363	SN	T023	C0038590
28521299	368	372	mice	T015	C0025929
28521299	377	390	real-time PCR	T063	C1709846
28521299	395	408	western blots	T059	C0949466
28521299	419	428	quatified	T081	C1709793
28521299	429	440	expressions	T045	C1171362
28521299	444	457	L-type Cav1.2	T116,T123	C1742148
28521299	462	496	Cav1.3 calcium channel α1 subunits	T116,T123	C1451807
28521299	504	506	SN	T023	C0038590
28521299	510	527	experimental mice	T008	C0003064
28521299	528	540	treated with	T061	C0332293
28521299	541	545	MPTP	T109,T131	C0000097
28521299	565	576	expressions	T045	C1171362
28521299	580	586	Cav1.2	T116,T123	C1742148
28521299	591	625	Cav1.3 calcium channel α1 subunits	T116,T123	C1451807
28521299	635	644	increased	T081	C0205217
28521299	651	655	MPTP	T109,T131	C0000097
28521299	656	665	treatment	T169	C1522326
28521299	678	683	weeks	T079	C0439230
28521299	698	706	observed	T169	C1441672
28521299	711	721	effects of	T080	C1704420
28521299	722	732	isradipine	T109,T121	C0071304
28521299	736	740	LTCC	T116,T123	C0288263
28521299	741	751	antagonist	T120	C0243076
28521299	756	760	MPTP	T109,T131	C0000097
28521299	763	770	induced	T046	C0007994
28521299	771	780	DA neuron	T025	C1512035
28521299	781	793	degeneration	T049	C0027746
28521299	798	825	iron accumulation in the SN	T033	C4022785
28521299	831	838	results	T033	C0683954
28521299	851	861	isradipine	T109,T121	C0071304
28521299	862	871	treatment	T169	C1522326
28521299	872	881	prevented	T169	C1292733
28521299	890	894	MPTP	T109,T131	C0000097
28521299	897	904	induced	T046	C0007994
28521299	905	911	Cav1.2	T116,T123	C1742148
28521299	916	950	Cav1.3 calcium channel α1 subunits	T116,T123	C1451807
28521299	951	964	up-regulation	T044	C0041904
28521299	972	974	SN	T023	C0038590
28521299	995	1005	isradipine	T109,T121	C0071304
28521299	1006	1015	prevented	T169	C1292733
28521299	1024	1028	MPTP	T109,T131	C0000097
28521299	1031	1038	induced	T046	C0007994
28521299	1039	1048	DA neuron	T025	C1512035
28521299	1049	1058	depletion	T169	C1880269
28521299	1066	1068	SN	T023	C0038590
28521299	1080	1088	restored	T061	C1283255
28521299	1093	1103	DA content	T059	C0201989
28521299	1111	1119	striatum	T023	C0010097
28521299	1145	1155	isradipine	T109,T121	C0071304
28521299	1156	1165	inhibited	T080	C0311403
28521299	1170	1178	increase	T169	C0442805
28521299	1182	1201	iron positive cells	T033	C2825141
28521299	1209	1211	SN	T023	C0038590
28521299	1219	1223	MPTP	T109,T131	C0000097
28521299	1226	1233	treated	T061	C0087111
28521299	1234	1238	mice	T015	C0025929
28521299	1252	1264	investigated	T169	C1292732
28521299	1269	1279	effects of	T080	C1704420
28521299	1280	1290	isradipine	T109,T121	C0071304
28521299	1294	1320	cellular iron accumulation	T033	C4022785
28521299	1328	1340	dopaminergic	T025	C1512035
28521299	1341	1358	MES23.5 cell line	T191	C0027819
28521299	1364	1371	studies	T062	C0008972
28521299	1384	1388	MPP+	T109,T131	C0000097
28521299	1389	1398	treatment	T169	C1522326
28521299	1399	1410	accelerated	T169	C0521110
28521299	1411	1422	iron influx	T044	C3548550
28521299	1430	1443	MES23.5 cells	T191	C0027819
28521299	1445	1454	Treatment	T061	C0087111
28521299	1460	1468	Bayk8644	T109,T121	C0004855
28521299	1477	1487	aggravated	T080	C1444749
28521299	1488	1505	iron accumulation	T033	C4022785
28521299	1507	1516	Treatment	T061	C0087111
28521299	1522	1532	isradipine	T109,T121	C0071304
28521299	1533	1542	prevented	T169	C1292733
28521299	1551	1555	MPP+	T109,T131	C0000097
28521299	1558	1565	induced	T046	C0007994
28521299	1566	1577	iron influx	T044	C3548550
28521299	1585	1598	MES23.5 cells	T191	C0027819
28521299	1606	1613	results	T033	C0683954
28521299	1627	1640	up-regulation	T044	C0041904
28521299	1644	1649	LTCCs	T116,T123	C0288263
28521299	1677	1686	DA neuron	T025	C1512035
28521299	1687	1699	degeneration	T049	C0027746
28521299	1707	1711	MPTP	T109,T131	C0000097
28521299	1714	1721	treated	T061	C0087111
28521299	1722	1726	mice	T015	C0025929
28521299	1732	1737	LTCCs	T116,T123	C0288263
28521299	1765	1776	iron influx	T044	C3548550
28521299	1782	1792	DA neurons	T025	C1512035
28521299	1798	1808	isradipine	T109,T121	C0071304
28521299	1813	1821	suppress	T169	C1260953
28521299	1822	1848	cellular iron accumulation	T033	C4022785
28521299	1853	1861	prevents	T169	C1292733
28521299	1862	1879	neurodegeneration	T049	C0027746